132 related articles for article (PubMed ID: 38403110)
1. CD63
Sun J; Du R; Li X; Liu C; Wang D; He X; Li G; Zhang K; Wang S; Hao Q; Zhang Y; Li M; Gao Y; Zhang C
Cancer Lett; 2024 Apr; 588():216747. PubMed ID: 38403110
[TBL] [Abstract][Full Text] [Related]
2. CD63
Gao Y; Li X; Zeng C; Liu C; Hao Q; Li W; Zhang K; Zhang W; Wang S; Zhao H; Fan D; Li M; Zhang Y; Zhang W; Zhang C
Adv Sci (Weinh); 2020 Nov; 7(21):2002518. PubMed ID: 33173749
[TBL] [Abstract][Full Text] [Related]
3. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
4. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
De Angelis C; Fu X; Cataldo ML; Nardone A; Pereira R; Veeraraghavan J; Nanda S; Qin L; Sethunath V; Wang T; Hilsenbeck SG; Benelli M; Migliaccio I; Guarducci C; Malorni L; Litchfield LM; Liu J; Donaldson J; Selenica P; Brown DN; Weigelt B; Reis-Filho JS; Park BH; Hurvitz SA; Slamon DJ; Rimawi MF; Jansen VM; Jeselsohn R; Osborne CK; Schiff R
Clin Cancer Res; 2021 Sep; 27(17):4870-4882. PubMed ID: 33536276
[TBL] [Abstract][Full Text] [Related]
5. PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Lin CC; Chang TC; Wang Y; Guo L; Gao Y; Bikorimana E; Lemoff A; Fang YV; Zhang H; Zhang Y; Ye D; Soria-Bretones I; Servetto A; Lee KM; Luo X; Otto JJ; Akamatsu H; Napolitano F; Mani R; Cescon DW; Xu L; Xie Y; Mendell JT; Hanker AB; Arteaga CL
Nat Commun; 2024 Mar; 15(1):2287. PubMed ID: 38480701
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Alves CL; Ehmsen S; Terp MG; Portman N; Tuttolomondo M; Gammelgaard OL; Hundebøl MF; Kaminska K; Johansen LE; Bak M; Honeth G; Bosch A; Lim E; Ditzel HJ
Nat Commun; 2021 Aug; 12(1):5112. PubMed ID: 34433817
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer.
Dang F; Nie L; Zhou J; Shimizu K; Chu C; Wu Z; Fassl A; Ke S; Wang Y; Zhang J; Zhang T; Tu Z; Inuzuka H; Sicinski P; Bass AJ; Wei W
Nat Commun; 2021 Sep; 12(1):5386. PubMed ID: 34508104
[TBL] [Abstract][Full Text] [Related]
8. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
Li Z; Razavi P; Li Q; Toy W; Liu B; Ping C; Hsieh W; Sanchez-Vega F; Brown DN; Da Cruz Paula AF; Morris L; Selenica P; Eichenberger E; Shen R; Schultz N; Rosen N; Scaltriti M; Brogi E; Baselga J; Reis-Filho JS; Chandarlapaty S
Cancer Cell; 2018 Dec; 34(6):893-905.e8. PubMed ID: 30537512
[TBL] [Abstract][Full Text] [Related]
9. Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders.
Wu X; Yang X; Xiong Y; Li R; Ito T; Ahmed TA; Karoulia Z; Adamopoulos C; Wang H; Wang L; Xie L; Liu J; Ueberheide B; Aaronson SA; Chen X; Buchanan SG; Sellers WR; Jin J; Poulikakos PI
Nat Cancer; 2021 Apr; 2(4):429-443. PubMed ID: 34568836
[TBL] [Abstract][Full Text] [Related]
10. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
Sammons S; Shastry M; Dent S; Anders C; Hamilton E
Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.
O'Sullivan CC; Clarke R; Goetz MP; Robertson J
JAMA Oncol; 2023 Sep; 9(9):1273-1282. PubMed ID: 37382948
[TBL] [Abstract][Full Text] [Related]
12. Exosomal miR-500a-5p derived from cancer-associated fibroblasts promotes breast cancer cell proliferation and metastasis through targeting USP28.
Chen B; Sang Y; Song X; Zhang D; Wang L; Zhao W; Liang Y; Zhang N; Yang Q
Theranostics; 2021; 11(8):3932-3947. PubMed ID: 33664871
[TBL] [Abstract][Full Text] [Related]
13. The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Wander SA; Cohen O; Gong X; Johnson GN; Buendia-Buendia JE; Lloyd MR; Kim D; Luo F; Mao P; Helvie K; Kowalski KJ; Nayar U; Waks AG; Parsons SH; Martinez R; Litchfield LM; Ye XS; Yu C; Jansen VM; Stille JR; Smith PS; Oakley GJ; Chu QS; Batist G; Hughes ME; Kremer JD; Garraway LA; Winer EP; Tolaney SM; Lin NU; Buchanan SG; Wagle N
Cancer Discov; 2020 Aug; 10(8):1174-1193. PubMed ID: 32404308
[TBL] [Abstract][Full Text] [Related]
14. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER
Shee K; Jiang A; Varn FS; Liu S; Traphagen NA; Owens P; Ma CX; Hoog J; Cheng C; Golub TR; Straussman R; Miller TW
FASEB J; 2019 Feb; 33(2):1644-1657. PubMed ID: 30161001
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer-derived exosomes regulate cell invasion and metastasis in breast cancer via miR-146a to activate cancer associated fibroblasts in tumor microenvironment.
Yang SS; Ma S; Dou H; Liu F; Zhang SY; Jiang C; Xiao M; Huang YX
Exp Cell Res; 2020 Jun; 391(2):111983. PubMed ID: 32268136
[TBL] [Abstract][Full Text] [Related]
16. MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation.
Ma J; Li L; Ma B; Liu T; Wang Z; Ye Q; Peng Y; Wang B; Chen Y; Xu S; Wang K; Dang F; Wang X; Zeng Z; Jian Y; Ren Z; Fan Y; Li X; Liu J; Gao Y; Wei W; Li L
Nat Commun; 2024 Feb; 15(1):1871. PubMed ID: 38424044
[TBL] [Abstract][Full Text] [Related]
17. Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.
Haricharan S; Punturi N; Singh P; Holloway KR; Anurag M; Schmelz J; Schmidt C; Lei JT; Suman V; Hunt K; Olson JA; Hoog J; Li S; Huang S; Edwards DP; Kavuri SM; Bainbridge MN; Ma CX; Ellis MJ
Cancer Discov; 2017 Oct; 7(10):1168-1183. PubMed ID: 28801307
[TBL] [Abstract][Full Text] [Related]
18. PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.
Del Re M; Crucitta S; Lorenzini G; De Angelis C; Diodati L; Cavallero D; Bargagna I; Cinacchi P; Fratini B; Salvadori B; Ghilli M; Roncella M; Fontana A; Danesi R; Cucchiara F
Pharmacol Res; 2021 Jan; 163():105241. PubMed ID: 33049397
[TBL] [Abstract][Full Text] [Related]
19. Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation.
Quan C; Wu Z; Xiong J; Li M; Fu Y; Su J; Wang Y; Ning L; Zhang D; Xie N
Exp Hematol Oncol; 2023 Nov; 12(1):100. PubMed ID: 38037159
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.
Del Re M; Bertolini I; Crucitta S; Fontanelli L; Rofi E; De Angelis C; Diodati L; Cavallero D; Gianfilippo G; Salvadori B; Fogli S; Falcone A; Scatena C; Naccarato AG; Roncella M; Ghilli M; Morganti R; Fontana A; Danesi R
Breast Cancer Res Treat; 2019 Nov; 178(1):57-62. PubMed ID: 31346846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
